Colin Hill

Colin Hill is a prominent figure in the fields of artificial intelligence and precision medicine, currently serving as a Member of the Board of Directors at Fulcrum Therapeutics.2 He is the CEO and co-founder of Aitia, a company focused on AI applications in healthcare.3

Professional Background

Colin Hill has an extensive background in developing and commercializing AI solutions, particularly in the biopharmaceutical and managed care industries.2 He co-founded GNS Healthcare, a leading AI biosimulation company, in 2000 and served as its CEO.2 Under his leadership, GNS Healthcare launched the world's first Virtual Patients for multiple diseases, including Multiple Myeloma, Prostate Cancer, and Alzheimer's Disease.2

Board Positions

In addition to his role at Fulcrum Therapeutics, Colin Hill has held several other notable board positions:

• Currently serves on the board of Centrexion Therapeutics, a biotech company focused on developing non-opioid, non-addictive chronic pain drugs2
• Previously served on the board of Biotelemetry Inc. (NASDAQ: BEAT), acquired by Philips in 20212
• Former board member of PPD Inc. (NASDAQ: PPD), acquired by Thermo in 20212
• Founding board member of AesRx, a biopharmaceutical company focused on sickle cell disease treatments, acquired by Baxter in 20142

Location and Connections

Colin Hill is based in Cambridge, Massachusetts, and has over 500 connections on LinkedIn.1 His LinkedIn username is indeed colinhill1, as mentioned in the query.13

Colin Hill is recognized as a leading voice in AI and precision medicine, bringing valuable experience and insights to his role on the Board of Directors at Fulcrum Therapeutics.